MAIA Biotechnology Inc. (MAIA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has a cash flow conversion efficiency ratio of -0.191x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.31 Million) by net assets ($27.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MAIA Biotechnology Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how MAIA Biotechnology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of MAIA Biotechnology Inc. for a breakdown of total debt and financial obligations.
MAIA Biotechnology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MAIA Biotechnology Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asetek A/S
F:A31
|
0.018x |
|
Vakrangee Limited
NSE:VAKRANGEE
|
0.093x |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
-0.032x |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
0.017x |
|
Foodnamoo. Inc
KQ:290720
|
-0.211x |
|
Adicet Bio Inc
NASDAQ:ACET
|
-0.131x |
|
Unitronics
TA:UNIT
|
0.153x |
|
Axon Partners Group S.A.
MC:APG
|
0.065x |
Annual Cash Flow Conversion Efficiency for MAIA Biotechnology Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of MAIA Biotechnology Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see MAIA Biotechnology Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.38 Million | $-18.84 Million | -7.932x | -83.57% |
| 2024-12-31 | $3.63 Million | $-15.70 Million | -4.321x | +84.22% |
| 2023-12-31 | $477.51K | $-13.07 Million | -27.373x | -1825.30% |
| 2022-12-31 | $8.51 Million | $-12.10 Million | -1.422x | -216.61% |
| 2021-12-31 | $9.18 Million | $-4.12 Million | -0.449x | -139.36% |
| 2020-12-31 | $-1.62 Million | $-1.84 Million | 1.141x | +196.58% |
| 2019-12-31 | $1.32 Million | $-1.57 Million | -1.181x | -- |
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more